☰

Ross B. Fulton, Ph.D. - Publications

Affiliations: 
2010 Microbiology University of Iowa, Iowa City, IA 
Area:
Immunology, Microbiology Biology, Virology Biology
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Chan ASH, Kangas TO, Qiu X, Uhlik MT, Fulton RB, Ottoson NR, Gorden KB, Yokoyama Y, Danielson ME, Jevne TM, Michel KS, Graff JR, Bose N. Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies. Frontiers in Oncology. 12: 869078. PMID 35692755 DOI: 10.3389/fonc.2022.869078  0.438
2021 Truckenbrod EN, Burrack KS, Knutson TP, Borges da Silva H, Block KE, O'Flanagan SD, Stagliano KR, Hurwitz AA, Fulton RB, Renkema KR, Jameson SC. CD8 T cell self-tolerance permits responsiveness but limits tissue damage. Elife. 10. PMID 33929324 DOI: 10.7554/eLife.65615  0.497
2020 Raue A, Lu Y, Li O, Lu M, Pi J, Wu J, Feng M, Zhang Q, Arumugam S, Jin R, Wang Y, Fulton R, Delince M, Crivello J, Duda Z, et al. Abstract 2285: HFB10-1E1, a novel OX-40 agonistic antibody with a unique pharmacological profile and biomarker strategy Immunology. 80: 2285-2285. DOI: 10.1158/1538-7445.Am2020-2285  0.413
2019 Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ. Synergy between EphA2-ILs-DTXp, a novel EphA2 targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models. Molecular Cancer Therapeutics. PMID 31597714 DOI: 10.1158/1535-7163.Mct-19-0414  0.411
2019 Tam EM, Fulton RB, Sampson JF, Muda M, Camblin A, Richards J, Koshkaryev A, Tang J, Kurella V, Jiao Y, Xu L, Zhang K, Kohli N, Luus L, Hutto E, et al. Antibody-mediated targeting of TNFR2 activates CD8 T cells in mice and promotes antitumor immunity. Science Translational Medicine. 11. PMID 31578241 DOI: 10.1126/Scitranslmed.Aax0720  0.419
2019 Bose N, Ottoson NR, Qiu X, Harrison B, Lowe JR, Uhlik MT, Rathmann BT, Kangas TO, Jordan LR, Ertelt KE, Jonas AB, Walsh RM, Chan ASH, Fulton RB, Leonardo SM, et al. Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers. Journal of Immunology (Baltimore, Md. : 1950). PMID 30988115 DOI: 10.4049/Jimmunol.1801533  0.334
2019 Sampson JF, Kurella VB, Paragas V, Kumar S, Lulo JE, Qiu JA, Razlog M, Fulton RB, Camblin AJ, Richards JM, Wong CS, Koshkaryev A, Suchy JJ, Grabow S, Muda M, et al. Abstract 555: A novel human TNFR2 antibody (MM-401) modulates T cell responses in anti-cancer immunity Cancer Research. 79: 555-555. DOI: 10.1158/1538-7445.Sabcs18-555  0.546
2019 Richards J, Wong C, Koshkaryev A, Fulton R, Camblin A, Sampson J, Luus L, Suchy J, Grabow S, Kurella V, Kumar S, Lulo J, Qiu J, Jiao Y, Xu L, et al. Abstract 4846: MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory Cancer Research. 79: 4846-4846. DOI: 10.1158/1538-7445.Sabcs18-4846  0.416
2019 Fulton RB, Camblin A, Sampson JF, Richards J, Wong C, Koshkaryev A, Luus L, Jiao Y, Xu L, Paragas V, Razlog M, Muda M, Tam EM, Drummond DC, Raue A. Abstract 3270: Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity Cancer Research. 79: 3270-3270. DOI: 10.1158/1538-7445.Am2019-3270  0.511
2018 Fraser KA, Kangas T, Fulton RB, Leonardo SM, Harrison B, Yokoyama Y, Bose N, Graff JR, Uhlik M, Gorden KB. Abstract 3767: Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing Immunology. 78: 3767-3767. DOI: 10.1158/1538-7445.Am2018-3767  0.534
2018 Leonardo S, Fulton RB, Fraser KA, Kangas TO, Gorden KB, Harrison B, Jonas AL, Chan AS, Yokayama Y, Bose N, Graff JR, Uhlik M. Abstract B009: Imprime PGG, a soluble yeast b-glucan PAMP, activates both innate and adaptive immune effector cells, resulting in enhanced antitumor responses that synergize with anti-PD-1 antibody therapy Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B009  0.507
2017 Bose N, Gorden K, Chan A, Bykowski AJ, Ottoson N, Walsh D, Qiu X, Harrison B, Kangas T, Fraser K, Fulton R, Leonardo S, Uhlik M, Graff J. Abstract B29: Innate immune modulation: The novel immunotherapeutic Imprime PGG triggers the anti-cancer immunity cycle in concert with tumor-targeting, anti-angiogenic and checkpoint inhibitor antibodies Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B29  0.526
2017 Jonas AB, Chan AS, Qiu X, Fraser K, Ottoson N, Kangas T, Walsh R, Leonardo SM, Fulton R, Gorden K, Uhlik M, Graff J, Bose N. Abstract LB-199: Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-199  0.498
2017 Leonardo S, Ottosson N, Gorden K, Kangas T, Qiu X, Fulton R, Harrison B, Jonas A, Walsh R, Ertelt K, Lowe J, Huhn R, Graff J, Bose N, Uhlik MT. Abstract 3688: Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites Cancer Research. 77: 3688-3688. DOI: 10.1158/1538-7445.Am2017-3688  0.496
2017 Michel KS, Fulton RB, Leonardo SM, Gorden KB, Graff JR, Danielson ME. Abstract 1703: A novel tumor vaccine platform: direct conjugation of antigens to the β glucan PAMP Imprime PGG enhances antigen presentation and T cell priming Cancer Research. 77: 1703-1703. DOI: 10.1158/1538-7445.Am2017-1703  0.621
2016 Fulton RB, Leonardo SM, Michel KS, Danielson ME, Gorden KB, Graff JR. Abstract B019: Imprime PGG, a soluble β-glucan, binds to and activates dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B019  0.593
2016 Leonardo SM, Fulton RB, Wurst LR, Gorden KB, Jonas AB, Qui X, Chan AS, Graff JR. Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A160  0.433
2016 Ottoson NC, Huhn RD, Lowe J, Harrison B, Iglesias J, Rathmann B, Kangas T, Wurst LR, Qiu X, Chan A, Jonas AB, Fraser K, Walsh RM, Ertelt K, Leonardo SM, ... Fulton R, et al. Abstract B008: Imprime PGG, an intravenously administered beta glucan PAMP activates the innate immune system: A phase I clinical study to evaluate immunopharmacodynamic responses Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B008  0.488
2016 Fulton RB, Leonardo SM, Jonas AB, Fraser KA, Chan ASH, Ottoson NR, Danielson ME, Bose N, Graff JR, Gorden K. Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-089  0.59
2016 Jonas ALB, Chan AS, Ottoson NR, Qiu X, Fraser K, Kangas TO, Fulton R, Rathmann B, Graff JR, Bose N. Abstract LB-087: Imprime PGG drives adaptive immune resistance within the tumor microenvironment by modulating the myeloid compartment and enhances the efficacy of anti-PD1 antibody in vivo Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-087  0.399
2016 Leonardo SM, Fulton RB, Gorden KB, Fraser K, Harrison B, Kangas T, Jonas A, Yokoyama Y, Ottoson N, Bose N, Graff JR. Abstract LB-080: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-080  0.436
2016 Fraser K, Chan A, Fulton R, Leonardo S, Jonas A, Qiu X, Ottoson N, Kangas T, Gordon K, Graff J, Bose N. Abstract 2335: Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with αPD-L1 treatment in vivo Cancer Research. 76: 2335-2335. DOI: 10.1158/1538-7445.Am2016-2335  0.404
2015 Fulton RB, Hamilton SE, Xing Y, Best JA, Goldrath AW, Hogquist KA, Jameson SC. The TCR's sensitivity to self peptide-MHC dictates the ability of naive CD8(+) T cells to respond to foreign antigens. Nature Immunology. 16: 107-17. PMID 25419629 DOI: 10.1038/Ni.3043  0.559
2015 Fulton RB, Leonardo S, Michel K, Wurst L, Phelon T, Danielson M, Gorden K. Abstract LB-236: Imprime PGG conjugated directly to protein enables cross-presentation of antigen that generates multifunctional cytotoxic T cells Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-236  0.654
2015 Leonardo SM, Gorden K, Fulton R, Wurst L. Abstract 5034: Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity Cancer Research. 75: 5034-5034. DOI: 10.1158/1538-7445.Am2015-5034  0.554
2015 Fulton RB, Chan AS, Leonardo SM, Jonas AB, Qiu X, Ottoson NC, Kangas TO, Michel KS, Danielson ME, Graff JR, Bose N, Gorden K. Abstract A99: Imprime PGG, a soluble yeast β-glucan, induces dendritic cell maturation, upregulating co-stimulatory and activation markers to enhance antigen presentation and T cell priming Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A99  0.607
2013 Fulton RB, Weiss KA, Pewe LL, Harty JT, Varga SM. Aged mice exhibit a severely diminished CD8 T cell response following respiratory syncytial virus infection. Journal of Virology. 87: 12694-700. PMID 24049171 DOI: 10.1128/Jvi.02282-12  0.698
2011 Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. Journal of Immunology (Baltimore, Md. : 1950). 187: 3145-54. PMID 21844390 DOI: 10.4049/Jimmunol.1100764  0.694
2011 Jameson SC, Fulton RB. Not all naïve CD8 T cells are created equal. Immunology and Cell Biology. 89: 576-7. PMID 21483444 DOI: 10.1038/Icb.2011.27  0.585
2010 Fulton RB, Meyerholz DK, Varga SM. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. Journal of Immunology (Baltimore, Md. : 1950). 185: 2382-92. PMID 20639494 DOI: 10.4049/Jimmunol.1000423  0.771
2010 Khanolkar A, Fulton RB, Epping LL, Pham NL, Tifrea D, Varga SM, Harty JT. T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts. Journal of Immunology (Baltimore, Md. : 1950). 185: 1132-41. PMID 20554960 DOI: 10.4049/Jimmunol.0902749  0.767
2010 Fulton RB, Varga SM. Editorial: CD8 T cells cut back on calcium intake in the lungs. Journal of Leukocyte Biology. 87: 961-4. PMID 20515917 DOI: 10.1189/Jlb.0110035  0.763
2009 Fulton RB, Varga SM. Effects of aging on the adaptive immune response to respiratory virus infections. Aging Health. 5: 775. PMID 20174457 DOI: 10.2217/Ahe.09.69  0.641
2008 Fulton RB, Olson MR, Varga SM. Regulation of cytokine production by virus-specific CD8 T cells in the lungs. Journal of Virology. 82: 7799-811. PMID 18524828 DOI: 10.1128/Jvi.00840-08  0.746
Show low-probability matches.